Inactive Instrument

Oxford Immunotec Global PLC

OXFD

GB00BGFBB958

Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired.

March 07, 2021

The company expired its plan on March 8, 2021, on account of its acquisition by PerkinElmer (UK) Holdings Limited.

Latest news about Oxford Immunotec Global PLC

Oxford Immunotec Announces Use of T-SPOT®Discovery SARS-CoV-2 Kit	21-04-29	CI
Oxford Immunotec Global PLC will Change its Name to Oxford Immunotec Global Limited	21-03-09	CI
Oxford Immunotec Global PLC Announces Board Changes	21-03-08	CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from S&P Global BMI Index	21-03-08	CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from NASDAQ Composite Index	21-03-08	CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC.	21-03-07	CI
Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired.	21-03-07	CI
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection	21-03-04	CI
Oxford Immunotec Global : Plans to Market T Cell Immune Response Measurement Kit to COVID-19 in South Korea	21-02-08	MT
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea	21-02-08	CI
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-Cov-2 Kit and Include New Panel to Detect T Cells Reactive to Endemic Coronaviruses	21-02-04	CI
Oxford Immunotec Global : Teams With Valneva on COVID-19 Vaccine Candidate Testing	21-01-13	MT
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study	21-01-13	CI
Sector Update: Health Care Stocks Add to Early Rise, Supported by Biotech Companies	21-01-07	MT
Sector Update: Modest Advance for Health Care Stocks Despite Larger Gains for Biotechnology Sector	21-01-07	MT
OXFORD IMMUNOTEC GLOBAL : JP Morgan Downgrades Oxford Immunotec Global to Neutral From Overweight, Keeps $22 Price Target	21-01-07	MT
OXFORD IMMUNOTEC GLOBAL : Piper Sandler Downgrades Oxford Immunotec Global to Neutral from Overweight, Adjusts Price Target to $22 from $24	21-01-07	MT
DJ Industrial : Wall Street Sees Upbeat Open as US Congress Certifies Biden's Win After Capitol Chaos	21-01-07	MT
PerkinElmer : to Acquire Oxford Immunotec for $591 Million	21-01-07	MT
PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Oxford Immunotec Global PLC (NasdaqGM:OXFD for approximately $560 million.	21-01-06	CI
Transcript : Oxford Immunotec Global PLC - Analyst/Investor Day	20-12-17
Oxford Immunotec Global : Gets Approval for T-Cell Select Reagent Kit for Tuberculosis Testing in South Korea	20-12-10	MT
Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit	20-12-10	CI
Oxford Immunotec Global : Signs Exclusive Distributor Agreement with Riken Genesis for SARS-CoV-2 Kit	20-12-02	MT
Oxford Immunotec Global PLC Signs Exclusive Distributor Agreement with Riken Genesis, to Market the T-SPOT Discovery SARS-CoV-2 Kit for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection in Japan	20-12-02	CI

Chart Oxford Immunotec Global PLC

Duration

Period

More charts

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Sector

More about the company